A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.
Richard Jefferys, an expert in HIV cure research, spoke to TheBodyPro about this new case of HIV remission -- and the danger in rushing to publish these stories, especially for people who live with stigma.
The procedure used in this case was similar to that used in the only previously confirmed HIV cure case, "Berlin patient" Timothy Ray Brown, albeit with a somewhat less aggressive approach.
TheBodyPro is covering all the latest in HIV science at the biggest annual gathering of HIV researchers in the U.S. Here's a preview of what's to come.
This year at CROI 2018 a few studies tried to explore possible mechanisms for the association of increased myocardial infarction risk and abacavir use.
A retrospective analysis presented at CROI 2018 looked at risk of viral rebound in people who switched to lamivudine (Epivir, 3TC)-based dual antiretroviral therapy.
Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.
Most people who could benefit from pre-exposure prophylaxis are not accessing it, the U.S. Centers for Disease Control and Prevention revealed at this year's Conference on Retroviruses and Opportunistic Infections.